Notice of Approval of Product with Priority Review Voucher for MRESVIA
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
This notice announces the FDA's approval of the MRESVIA vaccine, which has redeemed a material threat medical countermeasure priority review voucher. This means MRESVIA, aimed at RSV prevention, was fast-tracked in the review process. Healthcare professionals and pharmaceutical companies are directly influenced by this approval as it impacts their work and the availability of vaccines.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- Approval of MRESVIA vaccine under priority review
- Utilization of a material threat medical countermeasure voucher
- Faster availability of RSV vaccine
Obligations
What this law requires
Healthcare professionals must utilize the MRESVIA vaccine for RSV prevention following its approval by the FDA.
Pharmaceutical companies must comply with the FDA guidelines regarding the use of the material threat MCM priority review voucher as outlined in the FD&C Act.
FDA must publish notices regarding the issuance of material threat MCM priority review vouchers and the approval of products redeeming these vouchers.
Data regarding the approval of MRESVIA must be made available by the FDA on their approved products website.
FDA must provide a link to the full text of section 565A of the FD&C Act on the relevant webpage regarding the material threat MCM Priority Review Voucher Program.